New combo therapy offers hope for hard-to-treat colorectal cancer
NCT ID NCT05627635
First seen Nov 11, 2025 · Last updated May 19, 2026 · Updated 24 times
Summary
This early-stage trial tests a combination of chemotherapy (FOLFOX), a blood vessel blocker (bevacizumab), and two immunotherapy drugs (botensilimab and balstilimab) in 20 people with a type of advanced colorectal cancer (MSS) that has spread. The goal is to find the safest dose and see if the combination can shrink tumors or slow the cancer's growth. Participants must have stable health and a life expectancy of at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.